EGFR and non-small cell lung carcinoma: These results are in agreement with a seminal preclinical trial by Engelman et al [118], showing that in NSCLC cell lines with EGFR mutations, prolonged exposure to EGFR TKIs led to the emergence of MET amplification as a resistance mechanism.